FNCA


FNCA   PANEL

image

Panel Top page
11th March 2024, Japan (+online)
Summary Report
Program
List of Participants
Presentations
20th June 2023, Japan (+online)
Summary Report
Program
List of Participants
Presentations
9th March 2022, Online
Summary Report
Program
List of Participants
Presentations
3rd-4th March 2021, Online
Summary Report
Program
List of Participants
Presentations
Mar 7th 2019, Japan
Summary Report
Program
List of Participants
Presentations
Mar 23th 2018, Japan
Summary Report
Program
List of Participants
Presentations
Mar 8-9th 2017, Japan
Summary Report
Program
List of Participants
Mar 10th 2016, Japan
Summary Report
Program
List of Participants
"Study Panel on the Approaches toward Infrastructure Development for Nuclear Power" (2009-)
6th: Aug 26th -27th 2014, Vietnam
Summary Report
Program
List of Participants
5th: Aug 22th - 23th 2013, Japan
Summary Report
Program
List of Participants
4th: Jul 26th - 27th 2012, Thailand
Summary Report
Program
List of Participants
3rd: Jul 5th - 6th 2011, Indonesia
Summary Report
Program
List of Participants
2nd: Jul 1st - 2nd 2010, Korea
Summary Report
Program
List of Participants
1st: Jul 30th 31st 2009, Tokyo
Summary Report
Program
List of Participants

"Study Panel for Cooperation in the Field of Nuclear Energy in Asia" (2007-2008)
2nd: Sep 1st - 2nd 2008, Tokyo
Summary Report
Program
List of Participants
1st: Oct 30th - 31st 2007, Tokyo
Summary Report
Program
List of Participants

"Role of Nuclear Energy for Sustainable Development in Asia" (2004-2006)
3rd: Nov 1st - 2nd 2006, Tsuruga
Summary Report
Program
List of Participants
2nd: Jan 25th - 26th 2006, Tokyo
Summary Report
Program
1st: Oct 20th - 21st 2004, Tokyo
Summary Report
Program
 


Forum for Nuclear Cooperation in Asia (FNCA)
“FNCA 2024 Study Panel (SP2024)

Participations of SP (in-person)
Participations of SP (online)

The 2024 Study Panel of Forum for Nuclear Cooperation in Asia (FNCA) was held in a hybrid manner on 11th March 2024, Tokyo, Japan, hosted by Japan Atomic Energy Commission (JAEC), Cabinet Office of Japan (CAO). The Panel was attended by representatives from 12 FNCA member countries (Australia, Bangladesh, China, Indonesia, Japan, Kazakhstan, Korea, Malaysia, Mongolia, The Philippines, Thailand and Vietnam) as well as representatives from Singapore (as an observer), and the invited keynote speakers from International Atomic Energy Agency and National Institutes for Quantum Science and Technology.

1. Background of Study Panel
The main theme of this Panel was "Production of Radioisotopes for Medical Use and Demand". In the meeting, keynote speeches were delivered related to production and utilization of medical radioisotopes around the world, and case-study presentations were made by member counties. Based on the keynotes and the case studies, useful information was exchanged.

2. Objectives of 2024Study Panel
The Study Panel aims at sharing knowledge, good practices and experiences to promote safe and peaceful use of nuclear science and technology among the member countries.

3. Summary of 2024 Study Panel

(1) Key-note speeches
 

1) "Japan's Action Plan for Production and Utilization of Medical Isotopes"
Dr. Tatsuya HIGASHI, Director, Dept. of Molecular Imaging and Theranostics, QST
The outline and implementation status of Medical Radioisotope Production and Utilization Action Plan, which was authorized in 2022 by Atomic Energy Commission of Japan, was introduced.
In the Action Plan, in order to realize domestic production of medical radioisotope and important isotope which is now largely depend on import from foreign countries, our country needs to realize research and development using research reactors or accelerators, and needs to consider policy of those implementation and promotion in an integrated way. The plan is aiming to have successes within 10 years in 4 items, which need to be dealt in order to achieve our goals.
The following reports were made regarding the specific implementation status.
1. Promote efforts toward domestic production and stable supply of important radioisotopes
As specific examples, the latest developments regarding 211At (astatine 211) production at QST and Osaka University, and 225Ac (actinium 225) production at the Japan Atomic Energy Agency (JAEA) and QST were introduced.
2. Developing systems and structures to promote the use of radioisotopes in medical settings
Currently, radiopharmaceuticals are subject to regulations not only as pharmaceuticals but also as radioisotopes, so they are under a complex regulatory system.
3. Promoting research and development that contributes to domestic production of radioisotopes
It was introduced that research and development of radioisotopes, which was first developed in Japan, is being carried out at venture companies, universities, and research institutes.
4. Strengthening research infrastructure, human resources, and networks for radioisotopes production and utilization
He introduced the strengthening of infrastructure that is being promoted mainly at universities and research institutes.
   
  2) "Trends in Medical Radioisotopes and Radiopharmaceuticals and the role of the IAEA"
Ms. Melissa A. Denecke, Director, Division of Physical and Chemical Sciences, IAEA
At first, Division of Physical and Chemical Sciences of IAEA has been introduced. It consists of 4 department, and covers wide range of field, such as, research reactor, accelerator, radiation chemistry, radiation technology, and nuclear data.
Then global manufacturing status of radioisotopes was explained, especially 99Mo/ 99mTc which will be used in SPECT, one kind of nuclear medicine examination. As of now, 6 research reactors are main supplier of the isotopes.
Regarding production of medical radioisotopes which is needed for radiopharmaceuticals, IAEA has been progressing some projects;
CRP: Production of Cyclotron-Based Gallium-68 Radioisotope and Related Radiopharmaceuticals
CRP: Zr-89 Production and Zr-89 Radiopharmaceuticals
Besides, IAEA has issued guidelines for radiopharmaceutical products in collaboration with WHO, and offer database about cyclotrons used for radionuclide production on its website.

(2) Case Studies
  Presentations were made by Vietnam, Thailand, Malaysia, Korea, Kazakhstan, and Indonesia with the theme of status, challenges, and best practice about production, shipment, and utilization about medical radioisotopes.
Dr. Pham Thanh Minh of Vietnam Atomic Energy Institute made a presentation about domestic production of medical radioisotopes. Almost all medical radioisotopes, i. e. , 131I,99mTc,32P are made by Da Lat nuclear reactor (TRIGA Mark II reactor with a capacity of 500 kW), and part of them were exported to Cambodia. And 5 cyclotrons produce 18F. The demand for radiopharmaceuticals is increasing, but importing medical radioisotopes is difficult under current procedures, so the country needs to respond future tight demand.
Mr. Thanete Doungta of Thailand Institute of Nuclear Technology made a presentation about domestic production of medical radioisotopes. Thailand produces medical radioisotopes by using TRIGA Mark II reactor at TINT and 7 cyclotron which are installed at universities and hospitals. TRIGA Mark II reactor produces 153Sm and 32P, and cyclotron produces 18F, 11C, 15O, and so on. In Thailand, there are some industries which produce or import radioisotopes, e. g. Biogenetech, Global Medical Solutions, Biomedia.
Dr. Nor Salita Binti Ali of Nuclear Medicine Department Ministry of Health made a presentation about domestic production of medical radioisotopes. In Malaysia, medical radioisotopes were made at 1 multi-purpose reactor and 5 cyclotrons, and some isotopes are imported. The country has a plan to start Alpha therapy with Astatine-211 near future. Demands for medical isotopes are increasing because cancer is fourth leading cause of death in Malaysia (12.6 percent in 2022).
Dr. Choong Mo Kang of Korea Institute of Radiological & Medical Sciences made a presentation about production of medical radioisotopes. The country produces 64Cu, 89Zr, and 124I with proton beam, and 211At, 117mSn, and 67Cu with alpha beam, using its 3 cyclotrons. As a future plan, the country would produce 203Pb, and combine it with 212Pb for theranostic. The country is considering not only using it domestically, but also exporting it oversees.
Ms. Natalya Koshnenko of National Nuclear Center of the Republic of Kazakhstan introduced 4 major institutions which produce and supply medial radioisotopes. At Institute of Nuclear Physics, 99mTc, 18F, and 131I are produced using WWR-K reactor. At Republican Diagnostic Center and Center for Nuclear Medicine and Oncology, 18F is produced using cyclotron.
Dr. Marlina of National Research and Innovation Agency or BRIN made a presentation. The country has 30 nuclear medicine centers, and the Ministry of Health has a plan to increase further the center. BRIN has 3 reactors and produces 53Sm, 177Lu, 32P, 99Mo/99mTc, 198Au, 192Ir, 153Gd etc. Medical Radioisotopes for diagnosis (99mTc, 131I, and 18F) and isotopes for therapy (131I, 153Sm, 177Lu) are produced in the country using 4 cyclotrons.

(3) Discussion
  Depending on the presentation of key-note speech and case study, all participants made a discussion. The chair suggested to discuss present and future topics for member countries, then discuss possible resolution by international or regional cooperation, and discuss concrete suggestions for those topics. The suggestion was adapted.
As a first topic, accuracy issues related to dosimetry and its control in internal irradiation and its control, and as a second topic, logistics of isotopes are proposed.
Dr. Uesaka of JAEC introduced current situation that in the side-event of general assembly of IAEA in 2022, astatine for radiation therapy become a topic, then discussion within specialist (Japan, U. S. and Europe) has started, and Korea has joined the discussion recently. So, there are some possibilities that the situation could develop to world-wide community near future.
In order to obtain these kinds of radioisotopes, there are some procedures, i. e. , negotiate with research institutes or universities which produces radioisotopes during international conferences or symposia. DOE already established supply system of radioisotopes but it is not necessarily efficient. If the international institutions such as IAEA should take initiatives to establish and operate this kind of supply system of radioisotopes, it is expected that the more efficient system would be developed.

4. Closing

Mr. NAOI Yosuke, commissioner of JAEC concluded the meeting with gratitude for all presenters and participants. He summarized each keynote speeches, country reports, and discussions and said "I hope that sharing perspectives and information at this meeting was beneficial to you all and contribute to your future activities. " Then the meeting was adjourned.

Forum for Nuclear Cooperation in Asia (FNCA)
“FNCA 2024 Study Panel”
Programme

Date: 11 March 2024
Venue: Hybrid
Organized by: Cabinet Office (CAO) Government of Japan
Japan Atomic Energy Committee (JAEC)
Chair Mr. NAOI Yosuke, Commissioner of JAEC
Theme “Production of Radioisotopes for Medical Use and Demand”

Monday, 11 March *JST
11:00 - 11:20

Session 1: Opening *OPEN TO PRESS
Chair: Mr. NAOI Yosuke, Commissioner of JAEC

  1. Opening Remarks: Mr. NAOI Yosuke
  2. Welcome Remarks: Dr. Mitsuru UESAKA, Chairperson of JAEC
  3. Self-Introduction of Participants
  4. Adoption of the Agenda
 
11:20 - 12:20

Session 2: Keynote Speech 1 *OPEN TO PRESS
Chair: Mr. NAOI Yosuke, Commissioner of JAEC

  1. “Japan’s Action Plan for Production and Utilization of Medical Isotopes”
    Dr. HIGASHI, Tatsuya, Director, National Institute for Quantum Science and Technology
   
12:00 - 13:00 (Lunch Break)
 
13:00 - 15:20

Session 3, Case Studies
3-1 Presentations from Member Countries (1)
Chair: Dr. Md Mustafizur Rahman, Bangladesh

  1. “Production of Radioisotopes for Medical Use and Demand in Vietnam”
    Dr. Pham Thanh Minh, Vietnam Atomic Energy Institute (VINATOM)
  2. “Production of Radioisotopes for Medical Use and Demand: Thailand"
    Mr. Thanete Doungta, Thailand Institute of Nuclear Technology
  3. “Production of Radioisotopes for Medical Use and Demand in Malaysia”
    Dr. Nor Salita Binti Ali, Nuclear Medicine Department Ministry of Health (MOH)

3-2 Presentations from Member Countries (2)
Chair: Ms. Natalya Koshnenko, Kazakhstan

  1. “Presentation from Korea, “Production and Application of Radioisotopes in KIRAMS, Korea”
    Dr. Choong Mo Kang, Korea Institute of Radiological & Medical Sciences (KIRAMS)
  2. “Production of Radiopharmaceuticals in Kazakhstan”
    Ms. Natalya Koshnenko, RSE National Nuclear Center of the Republic of Kazakhstan
  3. “Production and Demand of Medical Radioisotopes in Indonesia”
    Dr. Marlina, National Research and Innovation Agency (BRIN)
   
15:20 - 15:40 Break
   
15:40 - 16:20

Session 4: Keynote Speech 2 *OPEN TO PRESS
Chair: Mr. NAOI Yosuke, Japan

  1. “Trends in Medical Radioisotopes and Radiopharmaceuticals and the role of the IAEA”
    Dr. Melissa Denecke, Department Nuclear Sciences and Applications, IAEA
   
16:20 - 16:50 Session 5 Discussion
 Chair: Dr. Choong Mo Kang, Korea
  Discussion, All
   
16:20 - 16:30 Session 6, Closing
Closing Remarks: Mr. NAOI Yosuke

Forum for Nuclear Cooperation in Asia (FNCA)
“FNCA 2024 Study Panel”
List of Participants

■Participants from FNCA countries
Australia

Ms. Pippa AINLEY
Senior Advisor, International Affairs
ANSTO
*FNCA Coordinator of Australia

Bangladesh

Dr. Md Mustafizur Rahman
Chief Scientific Officer & Head,
Radioisotope Production Division,
Institute of Nuclear Science & Technology (INST)
Bangladesh Atomic Energy Commission (BAEC)

China

Mr. LONG Maoxiong
Deputy Secretary General
China Nuclear Energy Association (CNEA)

Mr. WANG Yibo
Chief Staff of Department of International Cooperation
China Nuclear Energy Association (CNEA)

Indonesia

Mr. Totti Tjiptosumirat
Executive Director of International Nuclear Agency - Indonesia, BRIN
National Research and Innovation Agency (BRIN)
*FNCA Coordinator of Indonesia

Dr. Marlina
Senior Researcher
National Research and Innovation Agency (BRIN)

Kazakhstan

Prof. Erlan Batyrbekov
Director General
National Nuclear Center of the Republic of Kazakhstan
*FNCA Coordinator of Kazakhstan

Ms. Natalya Koshnenko
Head of Organizational Department
National Nuclear Center of the Republic of Kazakhstan

Republic of Korea

Dr. Choong Mo Kang
Senior Researcher
Korea Institute of Radiological & Medical Sciences (KIRAMS)

Dr. Kyo Chul Lee
Principal Researcher
Director of Div. of RI Applied Science
Korea Institute of Radiological & Medical Sciences (KIRAMS)

Ms. Naheun Kim
Researcher
Korea Nuclear International Cooperation Foundation (KONICOF)

Malaysia

Dr. Muhammad Rawi Bin Mohamed Zin
Deputy Director General (R&D Program)
Malaysian Nuclear Agency (Nuclear Malaysia)
*FNCA Coordinator of Malaysia

Dr. Nor Salita Binti Ali
Nuclear Medicine Physician and Head of Department
Nuclear Medicine Department
Ministry of Health (MOH)

Mongolia

Ms. Enkhtsetseg Lkhaashid
Officer of Nuclear Technology Department
The Executive Office of the Nuclear Energy Commission (NEC) of Mongolia

The Philippines

Mr. Neil Raymund Diaz Guillermo
Supervising Science Research Specialist
Philippine Nuclear Research Institute (PNRI)
*FNCA Coordinator of the Philippines

Ms. Maria Teresa L. Borras
Senior Science Research Specialist
Philippine Nuclear Research Institute (PNRI)

Ms. Rizalina G. Osorio
Science Research Specialist II
Philippine Nuclear Research Institute (PNRI)

Thailand

Ms. Moleephan Dangprasert
Manager of Radioisotope Center
Thailand Institute of Nuclear Technology

Mr. Sanguansak Hykunya
Nuclear scientist
Thailand Institute of Nuclear Technology

Ms. Suppamat Makjan
Nuclear scientist
Thailand Institute of Nuclear Technology

Mr. Thanete Doungta
Head of Radioisotope Production Section
Thailand Institute of Nuclear Technology

Mrs. Thidarat Kohud
Nuclear scientist
Thailand Institute of Nuclear Technology

Mr. Veerawit Piamvimol
Pharmacist
Thailand Institute of Nuclear Technology

Ms. Anchisa Suratanachaigarn
Nuclear Scientist
Thailand Institute of Nuclear Technology

Mr. Chotiwid Wiriyachailerd
Nuclear scientist
Thailand Institute of Nuclear Technology

Ms. Hasana Laewoharn
Nuclear scientist
Thailand Institute of Nuclear Technology

Ms. Kanyapat Lumyong
Nuclear scientist
Thailand Institute of Nuclear Technology

Ms. Krittika Somruedee
QA pharmacist
Thailand Institute of Nuclear Technology

Ms. Chatchawan Mansaithong
International Cooperation Officer
Thailand Institute of Nuclear Technology

Ms. Worada Jarupoonphol
International Cooperation Officer
Thailand Institute of Nuclear Technology

Vietnam

Dr. CAO Dong Vu
Director
Dalat Nuclear Research Institute
Vietnam Atomic Energy Institute (VINATOM)
*FNCA Coordinator of Vietnam

Dr. Pham Thanh Minh
Director of the Center for research and production radioisotopes
Dalat Nuclear Research Institute
Vietnam Atomic Energy Institute (VINATOM)

Singapore

Mr. Ang Kok Kiat
Group Director (Radiation Protection and Nuclear Science Group)
National Environment Agency

Mr. Say Yueyang, Symus
Engineer (Radiation Protection and Nuclear Science Group)
National Environment Agency

Prof. CHUNG Keng Yeow
Director
Singapore Nuclear Research and Safety Initiative
National University of Singapore

Dr. Wang Lian Chek Michael
Chair
Division of Radiation Oncology, National Cancer Centre Singapore

Ms. Ang Zuo Jin
Senior Assistant Director
Energy and Climate Policy Division
Ministry of Sustainability and the Environment

Mr. Low En Zuo Joel
Medical Physicist
Singapore General Hospital

■IAEA

Dr. Melissa Denecke
Director of Physical and Chemical Sciences,
Department of Nuclear Sciences and Applications
International Atomic Energy Agency (IAEA)

■Japan

QST

Dr. HIGASHI Tatsuya
Director
Department of Molecular Imaging and Theranostics
Institute for Quantum Medical Science (iQMS)
National Institutes for Quantum Science and Technology (QST)

Cabinet Office, Government of Japan (CAO)

(1) Japan Atomic Energy Commission (JAEC)
Dr. UESAKA Mitsuru
Chairman
Japan Atomic Energy Commission (JAEC)

Mr. NAOI Yosuke
Commissioner
Japan Atomic Energy Commission (JAEC)

Dr. OKADA Yukiko
Commissioner
Japan Atomic Energy Commission (JAEC)

Dr. HATAZAWA Jun
Special Advisor, Atomic Energy Commission (JAEC)
Chief Executive Director, Japan Radioisotope Association

(2) Secretariat of Japan Atomic Energy Commission (JAEC)
Dr. TOKUMASU Shinji
Deputy Director General for Science, Technology and Innovation Policy
Cabinet Office of Japan (CAO)

Mr. YAMADA Tetsuya
Director for Atomic Energy and International Affairs
Secretariat of Science, Technology and Innovation Policy
Cabinet Office of Japan (CAO)

Mr. SAKUMA Akira
Deputy-Director
Office for Atomic Energy Policy
Secretariat of the Atomic Energy Commission
Cabinet Office of Japan (CAO)

Ms. TANADA Mizue
Technical Counsellor
Office of Atomic Energy Policy
Secretariat of the Atomic Energy Commission
Cabinet Office of Japan (CAO)

Ms. FUKANO Keiko
Senior Researcher
Office of Atomic Energy Policy
Secretariat of the Atomic Energy Commission
Cabinet Office of Japan (CAO)

Mr. YAMADA Katsumi
Technical Counsellor
Office for Atomic Energy Policy
Secretariat of the Atomic Energy Commission
Cabinet Office of Japan (CAO)

Ms. NOTO Koko
Senior Researcher
Office for Atomic Energy Policy
Secretariat of the Atomic Energy Commission
Cabinet Office of Japan (CAO)

Ministry of Education, Culture, Sports, Science and Technology (MEXT)

Mr. KAWAHARA Taku
Director
International Nuclear Cooperation
Research and Development Bureau
Ministry of Education, Culture, Sports, Science and Technology (MEXT)

Ms. OKUYAMA Chikako
Unit Chief
International Nuclear and Fusion Energy Affairs Division
Research and Development Bureau
Ministry of Education, Culture, Sports, Science and Technology (MEXT)

Mr. OBATA Ryoji
Deputy Director
International Nuclear and Fusion Energy Affairs Division
Research and Development Bureau
Ministry of Education, Culture, Sports, Science and Technology (MEXT)

Mr. KUMAGAE Koichi
Researcher
International Nuclear and Fusion Energy Affairs Division
Research and Development Bureau
Ministry of Education, Culture, Sports, Science and Technology (MEXT)

Ms. NAKAHARA Risa
Administrative Researcher
International Nuclear and Fusion Energy Affairs Division
Research and Development Bureau
Ministry of Education, Culture, Sports, Science and Technology (MEXT)

Japan Radioisotope Association

Dr. UWAMINO Yoshitomo
Japan Radioisotope Association

Mr. INOUE Takayuki
Japan Radioisotope Association

Mr. UETAKE Tomonori
Japan Radioisotope Association

Ms. SAKODA Sachiko
Japan Radioisotope Association

Mr. INAGE Toshimitsu
Japan Radioisotope Association
Scientific Support Division

Coordinator

Dr. TAMADA Masao
FNCA Coordinator of Japan

Advisor

Mr. WADA Tomoaki
FNCA Advisor of Japan

Forum for Nuclear Cooperation in Asia (FNCA)
“FNCA 2024 Study Panel”
Presentations

■Session 2 Keynote Speech I 4.7MB
■Session 3-1 Case Study-1 (Vietnam) 2.2MB
■Session 3-2 Case Study-2 (Thailand) 2.1MB
■Session 3-3 Case Study-3 (Malaysia) 0.6MB
■Session 3-4 Case Study-4 (Korea) 10.7MB
■Session 3-5 Case Study-5 (Kazakhstan) 3.5MB
■Session 3-6 Case Study-6 (Indonesia) 0.9MB
■Session 4 Keynote Speech II 4.5MB
Forum for Nuclear Cooperation in Asia